-
Repurposing Lopinavir and FDA Drugs to Inhibit MERS-CoV Repl
2026-05-26
de Wilde et al. systematically screened FDA-approved drugs and identified four compounds—including Lopinavir (ABT-378)—that inhibit MERS-CoV replication in cell culture. These findings provide a rapid translational foundation for exploring established antivirals in emerging coronavirus outbreaks.
-
Metformin Hydrochloride Workflows: Ossification & Metabolic
2026-05-26
Metformin Hydrochloride (Metformin HCl) is advancing research on both glucose metabolism and heterotopic ossification by targeting key molecular pathways such as AMPK and Nr4a1/Wnt/β-catenin. This article delivers protocol enhancements, troubleshooting strategies, and practical guidance for maximizing reproducibility with APExBIO’s high-purity reagent.
-
Frizzled5 Links Cholesterol Metabolism to Wnt/β-Catenin in C
2026-05-25
This study reveals that Frizzled5 uniquely senses cholesterol via its extracellular linker region, driving Wnt/β-catenin signaling crucial for pancreatic cancer growth. The work uncovers a mechanistic bridge between lipid metabolism and oncogenic signaling, with implications for targeted therapeutic intervention.
-
Ethacridine Lactate Monohydrate for Reliable Microbial Contr
2026-05-25
Ethacridine lactate monohydrate is redefining microbial inhibition in high-sensitivity cell and chromatin assays, offering rapid solubility and robust antiseptic action. Leveraging findings from super-enhancer research, this guide empowers researchers to optimize protocols and ensure data integrity in stem cell and epigenetic workflows.
-
Tofacitinib (CP-690550): Redefining RA Macrophage Modulation
2026-05-24
This article explores the breakthrough role of tofacitinib (CP-690550, Tasocitinib) as a JAK1/3-selective inhibitor in reversing both inflammation and mitochondrial dysfunction in rheumatoid arthritis (RA) macrophages. By integrating mechanistic insights, key experimental evidence, and translational workflow guidance, we provide strategic direction for researchers targeting cytokine signaling and immune cell metabolism. APExBIO’s Tofacitinib is positioned as a gold-standard research tool for advanced immune modulation studies.
-
Tofacitinib Citrate (CP-690550): Precision in Immune Researc
2026-05-23
Tofacitinib citrate (CP-690550 citrate) stands out for its selective JAK3 inhibition, empowering researchers to dissect immune regulation and inflammatory pathways with nanomolar precision. This article delivers actionable workflows, troubleshooting strategies, and novel assay insights, bridging established protocols with emerging cardiovascular findings.
-
L-Alanyl-L-Glutamine: Protocols and QC for GI Barrier Studie
2026-05-22
L-Alanyl-L-Glutamine (SKU B8228) is designed to support research workflows focused on intestinal mucosa protection and barrier function enhancement, especially where glutamine stability or solubility is a concern. It should not be substituted in protocols requiring glutamine analogs with different solubility or metabolic properties, and is unsuitable for use in organic solvents.
-
JAK Inhibitors and Endothelial Dysfunction in Inflammation
2026-05-22
This study systematically compares the vascular effects of several JAK inhibitors, including tofacitinib citrate, on human endothelial cells under inflammatory conditions. Its findings clarify the differential impact of JAK inhibition on cytokine signaling, adhesion molecule expression, and procoagulant activity, offering new insight into the cardiovascular safety profile of these agents in immune regulation research.
-
Metoprolol Tartrate: Precision β1 Blockade in Translational
2026-05-21
This thought-leadership article examines the mechanistic selectivity and translational value of Metoprolol Tartrate, a β1-adrenergic blocking agent, for researchers investigating cardiovascular and hematopoietic regeneration. Drawing on recent landmark studies, it provides actionable guidance for experimental design and positions APExBIO’s Metoprolol Tartrate as a gold-standard tool, advancing the conversation beyond standard product listings.
-
Lysis Buffer Advances for Mouse Tail Genotyping: Beyond Extr
2026-05-21
Explore how a specialized lysis buffer, a key rapid genotyping kit component, shapes DNA extraction from mouse tail tissue and impacts downstream genetic research. This article offers new insights into assay optimization, comparative protocols, and translational relevance.
-
Gingerenone A Reverses Sunitinib Resistance in Renal Cancer
2026-05-20
This study reveals that gingerenone A, a natural compound, suppresses LDHA-mediated glycolysis and restores sensitivity to sunitinib in renal cell carcinoma models. The findings highlight a metabolic-based strategy to overcome drug resistance and point to actionable assays for studying cell proliferation in this context.
-
nor-Binaltorphimine Dihydrochloride in Opioid Receptor Signa
2026-05-20
nor-Binaltorphimine dihydrochloride, a potent κ-opioid receptor antagonist, enables precise dissection of neural circuits involved in pain modulation and opioid signaling. This article translates recent circuit-mapping breakthroughs into actionable workflows, troubleshooting, and protocol enhancements for advanced pain and addiction research.
-
AMPK’s Dual Role in Autophagy Regulation Under Energy Stress
2026-05-19
Recent research redefines the function of AMPK in autophagy, demonstrating that it suppresses, rather than promotes, autophagy initiation during glucose starvation. This nuanced regulation has significant implications for the interpretation of autophagy inhibition strategies and the use of Vps34 inhibitors like SAR405 in metabolic and disease models.
-
Metoprolol in Translational Research: Pathways Beyond Cardio
2026-05-19
Explore how Metoprolol, a selective beta1-adrenoceptor antagonist, is transforming advanced cardiovascular and cancer biology research. This article uniquely bridges pharmacokinetic variability with assay design, setting it apart from conventional reviews.
-
ERK5 and MEK Inhibition in Vitamin D3-Induced AML Differenti
2026-05-18
This article discusses how the ERK5/MAPK pathway shapes 1α,25-(OH)₂ vitamin D₃-induced terminal differentiation in myeloid leukemia cells, highlighting novel mechanistic insights into cell cycle regulation beyond the well-studied ERK1/2 axis. The findings inform new combinatorial strategies for cancer research, with practical implications for targeting MAPK pathways in leukemia.